Has the CONVINCE trial convinced the nephrology and dialysis community?

Ann Transl Med. 2024 Oct 20;12(5):99. doi: 10.21037/atm-24-50. Epub 2024 Sep 5.

Authors

Julien Moury¹, Gauthier Nendumba¹, Arnaud Robert¹, Benedicte Hauquiert¹, Ovidiu Vornicu^{1

2}, Sydney Blackman³, Emily Perriens⁴, Nathan De Lissnyder⁴, Andriy Shchukin⁴, Farah El Yaakoubi⁴, Clara Saad⁴, Cyril Schmit⁴, Anne-Sophie Dincq^{1

2}, Patrick Evrard¹, Pierre Bulpa¹, Isabelle Michaux¹, Patrick M Honore¹

Affiliations

¹ ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
² ICU and Anesthesiology Departments, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
³ Department of gynecology, Centre Hospitalier interregional Edith Cavell (Chirec Hospital), Brussels, Belgium.
⁴ Faculty of Medicine, ULB University, Brussels, Belgium.

No abstract available

Keywords: High-flux hemodialysis (HFH); applicability; chronic dialysis patients; high-dose hemodiafiltration; improved prognosis.

Publication types

Editorial
Comment